Guru Sonpavde, MD

Articles

Unmet Needs and the Evolving Role of MRD Monitoring in MIBC

December 1st 2025

Discover the latest insights on ctDNA testing and its impact on relapse risk in muscle-invasive bladder cancer post-surgery.

Risk Stratification and Surveillance After

December 1st 2025

Experts discuss the evolving treatment landscape for muscle-invasive bladder cancer, highlighting the shift towards perioperative approaches and the role of biomarkers.

Analyzing the Role of ctDNA and Adjuvant

November 20th 2025

Experts discuss the evolving role of ctDNA in adjuvant therapy post-cystectomy, highlighting its prognostic value and implications for treatment decisions.

Biomarker, Diagnosis, and Evolving Treatment Paradigm in MIBC

November 20th 2025

Recent discussions highlight the significance of ctDNA in adjuvant therapy post-cystectomy, revealing its potential to predict patient outcomes and guide treatment decisions.

Advancements in Perioperative Therapy for MIBC

November 13th 2025

Experts discuss the promising results of the Niagara trial, highlighting benefits of cisplatin and durvalumab for unfit patients in cancer treatment.

Novel Neoadjuvant Therapies in MIBC

November 13th 2025

Experts discuss advancements in muscle invasive bladder cancer, focusing on innovative testing and treatment strategies to enhance patient outcomes.

Dr Sonpavde on an Exploratory Analysis of CheckMate 901 in Metastatic Urothelial Cancer

October 14th 2024

Guru P. Sonpavde, MD, discusses topline data from an exploratory analysis of CheckMate 901 in metastatic urothelial cancer.

Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

July 24th 2024

Drs Park and Sonpavde discuss findings from the phase 1 DAD trial, as well as a schema for the frontline management of metastatic urothelial carcinoma.

Park and Sonpavde on Nivolumab Plus Gemcitabine/Cisplatin in Cisplatin-Eligible Urothelial Cancer

July 10th 2024

Drs Park and Sonpavde discuss the CheckMate901 trial, which showed survival improvements with nivolumab plus chemotherapy in metastatic urothelial cancer.

Park and Sonpavde on Considerations for Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

May 30th 2024

Drs Park and Sonpavde emphasize their insights on the topline data from the EV-302 trial of enfortumab vedotin plus pembrolizumab in urothelial carcinoma.

Dr Sonpavde on the Potential Impact of the THOR Study in FGFR2/3-Altered Urothelial Carcinoma

June 29th 2023

Guru P. Sonpavde, MD, discusses the potential impact of the phase 3 THOR study evaluating erdafitinib vs chemotherapy in patients with advanced or metastatic urothelial cancer harboring FGFR2/3 alterations.

Dr. Sonpavde on Predicting 5-year Survival Outcomes in MIBC Using Neural Network Analysis

February 28th 2023

Guru P. Sonpavde, MD, discusses the methodology and key results from an analysis of the Cancer Genome Atlas in muscle-invasive bladder cancer.

Dr. Sonpavde on Anticipated Data in Bladder Cancer

May 12th 2021

Guru P. Sonpavde, MD, discusses anticipated data in bladder cancer.

Dr. Sonpavde on the Potential for Neoadjuvant Immunotherapy in Bladder Cancer

June 7th 2019

Guru P. Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses the potential for neoadjuvant immunotherapy in bladder cancer.

Dr. Sonpavde on Accelerated Approval of Erdafitinib in Bladder Cancer

May 3rd 2019

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses the FDA accelerated approval of erdafitinib (Balversa) in bladder cancer.

Dr. Sonpavde on the Role of Durvalumab in Platinum-Refractory Bladder Cancer

April 24th 2019

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses the role of durvalumab in the treatment of patients with platinum-refractory bladder cancer.

Dr. Sonpavde on Remaining Questions With Immunotherapy in Bladder Cancer

September 19th 2018

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses remaining questions with immunotherapy in bladder cancer.

Dr. Sonpavde on Immunotherapy Plus Chemotherapy in Bladder Cancer

April 4th 2018

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses immunotherapy plus chemotherapy in bladder cancer.

Dr. Sonpavde on the Next Steps for Atezolizumab in Urothelial Carcinoma

March 22nd 2018

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses the next steps for the prognostic model for atezolizumab (Tecentriq) in patients with urothelial carcinoma.

Dr. Sonpavde on Novel Prognostic Marker for Atezolizumab in Bladder Cancer

February 20th 2018

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses a novel prognostic marker for patients with advanced bladder cancer being treated with the PD-L1 inhibitor atezolizumab (Tecentriq).